- Home
- BFRI vs BLRX Comparison
BFRI vs BLRX Comparison
Compare BFRI & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BFRI | BLRX |
|---|---|---|
| Founded | 1997 | 2003 |
| Country | United States | Israel |
| Employees | 94 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 12.6M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | BFRI | BLRX |
|---|---|---|
| Price | $1.14 | $3.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.75 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 121.5K | 22.0K |
| Earning Date | 05-13-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.36 | N/A |
| Revenue Next Year | $16.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $2.15 |
| 52 Week High | $1.19 | $7.77 |
Technical Indicators
Market Signals| Indicator | BFRI | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 64.13 | 63.48 |
| Support Level | $0.79 | $2.66 |
| Resistance Level | $1.17 | $3.93 |
| Average True Range (ATR) | 0.07 | 0.23 |
| MACD | -0.00 | 0.10 |
| Stochastic Oscillator | 73.68 | 74.40 |
Price Performance
Historical ComparisonAbout BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.